Search

Your search keyword '"Minces, Lucio R."' showing total 11 results
Start Over Author "Minces, Lucio R."
11 results on '"Minces, Lucio R."'

1. Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States

Author

Franco-Paredes, Carlos, primary, Garcia-Creighton, Elizabeth, additional, Henao-Martínez, Andrés, additional, Kallgren, Diane L., additional, Banjade, Rashmi, additional, Dyer, Jon A., additional, Nelson, Taylor, additional, Zaesim, Araya, additional, Peluso, Michael J., additional, Jain, Vivek, additional, Lee, Dong Heun, additional, Minces, Lucio R., additional, Wirshup, Mary, additional, Sierra Hoffman, Miguel, additional, Katsolis, Jenn, additional, Brust, Karen, additional, Giron, Jose, additional, Smiarowski, Lauren, additional, Hoosepian-Mer, Pauline A., additional, and Stryjewska, Barbara, additional

Published
2022
Full Text
View/download PDF

4. Enterococcus faecalis Septicemia and Vertebral Osteomyelitis after Transrectal Ultrasound Guided Biopsy of the Prostate

Author

Virji, Ayaz, Minces, Lucio R., and Abbass, Zargham

Subjects
Article Subject, urologic and male genital diseases
Abstract

Transrectal ultrasound guided prostate biopsy (TRUS) has rarely been associated with disseminated infection, yet the occurrence appears to be increasing. Resistance to fluoroquinolones, the most commonly used prophylaxis, is one of the likely causes, with Escherichia coli being the most commonly reported cause of these infections. Herein we present what is, to our knowledge, the first case of Enterococcus faecalis septicemia and vertebral osteomyelitis after TRUS. Previously reported cases of this condition are referenced also.

Published
2015
Full Text
View/download PDF

7. Ganciclovir-Resistant Cytomegalovirus Infections among Lung Transplant Recipients Are Associated with Poor Outcomes despite Treatment with Foscarnet-Containing Regimens

Author

Minces, Lucio R., primary, Nguyen, M. Hong, additional, Mitsani, Dimitra, additional, Shields, Ryan K., additional, Kwak, Eun J., additional, Silveira, Fernanda P., additional, Abdel-Massih, Rima, additional, Pilewski, Joseph M., additional, Crespo, Maria M., additional, Bermudez, Christian, additional, Bhama, Jay K., additional, Toyoda, Yoshiya, additional, and Clancy, Cornelius J., additional

Published
2014
Full Text
View/download PDF

8. Staphylococcus aureus infections in the early period after lung transplantation: Epidemiology, risk factors, and outcomes

Author

Shields, Ryan K., primary, Clancy, Cornelius J., additional, Minces, Lucio R., additional, Kwak, Eun J., additional, Silveira, Fernanda P., additional, Abdel Massih, Rima C., additional, Toyoda, Yoshiya, additional, Bermudez, Christian, additional, Bhama, Jay K., additional, Shigemura, Norihisa, additional, Pilewski, Joseph M., additional, Crespo, Maria, additional, and Hong Nguyen, M., additional

Published
2012
Full Text
View/download PDF

11. Ganciclovir-Resistant Cytomegalovirus Infections among Lung Transplant Recipients Are Associated with Poor Outcomes despite Treatment with Foscarnet-Containing Regimens

Author

Minces, Lucio R., Nguyen, M. Hong, Mitsani, Dimitra, Shields, Ryan K., Kwak, Eun J., Silveira, Fernanda P., Abdel-Massih, Rima, Pilewski, Joseph M., Crespo, Maria M., Bermudez, Christian, Bhama, Jay K., Toyoda, Yoshiya, and Clancy, Cornelius J.

Abstract

ABSTRACTGanciclovir-resistant cytomegalovirus (CMV) infections are reported infrequently among lung transplant recipients receiving extended valganciclovir prophylaxis. We performed a single-center, retrospective review of ganciclovir-resistant CMV infections in a program that employed valganciclovir prophylaxis for ≥6 months after lung transplant. CMV infections were diagnosed in 28% (170/607) of patients. UL97 mutations were detected in 9.4% (16/170) of CMV-infected patients at a median of 8.5 months posttransplant (range, 5 to 21) and despite prophylaxis for a median of 7 months (range, 4 to 21). UL97 mutations were canonical; 25% (4/16) of strains carried concurrent UL54 mutations. Ganciclovir-resistant CMV was more likely with breakthrough infections (75% [12/16] versus 19% [30/154]; P= 0.00001) and donor positive/recipient negative (D+/R−) serostatus (75% versus 45% [69/154]; P= 0.03). The median whole-blood CMV load was 4.13 log10copies/cm3(range, 2.54 to 5.53), and 93% (14/15) of patients had low-moderate immune responses (Cylex Immunoknow). Antiviral therapy was successful, failed, or eradicated viremia followed by relapse in 12% (2/16), 31% (5/16), and 56% (9/16) of patients, respectively. Eighty-seven percent (14/16) of patients were treated with foscarnet-containing regimens; toxicity developed in 78% (11/14) of these. Median viral load half-life and time to viremia eradication among foscarnet-treated patients were 2.6 and 23 days, respectively, and did not correlate with protection from relapse. Sixty-nine percent (11/16) of patients developed CMV pneumonitis, and 25% (4/16) died of it. Serum viral load was independently associated with death among foscarnet-treated patients (P= 0.04). In conclusion, ganciclovir-resistant CMV infections remained a major cause of morbidity and mortality following lung transplantation. Foscarnet-based regimens often eradicated viremia rapidly but were ineffective in the long term and limited by toxicity.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results